Arcus Biosciences, INC Form 4 insider transactions

Juan C. Jaen, President of Arcus Biosciences, Inc., sold 68,569 shares of common stock on July 9, 2026.

Arcus Biosciences President Juan C. Jaen reported the sale of company stock totaling over 31,000 shares across multiple transactions executed between June 22 and June 24, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences director Nicole Lambert was granted 5,700 restricted stock units and 16,900 stock options as part of annual compensation.

Director Patrick Machado acquired 5,700 restricted stock units and 16,900 stock options in Arcus Biosciences, Inc.

Director Yasunori Kaneko acquired 5,700 restricted stock units and 16,900 stock options in Arcus Biosciences, Inc.

General Counsel Carolyn C. Tang exercised 34,090 stock options in Arcus Biosciences, Inc. on June 11, 2026.

Director David L. Lacey was granted 5,700 restricted stock units and 16,900 stock options by Arcus Biosciences.

Director Kathryn E. Falberg was granted 5,700 restricted stock units and 16,900 stock options by Arcus Biosciences.

Director Antoni Ribas acquired 5,700 restricted stock units and 16,900 stock options in Arcus Biosciences, Inc.

Director Andrew J. Perlman was granted 5,700 restricted stock units and 16,900 stock options by Arcus Biosciences.

Chief Accounting Officer Alexander Azoy sold 2,562 shares of Arcus Biosciences common stock via a Rule 10b5-1 trading plan.

Arcus Biosciences Director Antoni Ribas reported transactions involving common stock, including a gift and the disposition of shares.

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, has reported the sale of common stock under a pre-arranged trading plan.

Arcus Biosciences' Chief Medical Officer, Richard Markus, was granted 24,000 restricted stock units and options to purchase 96,000 shares of common stock.

Arcus Biosciences CEO Terry J. Rosen received grants of 79,000 restricted stock units and options to purchase 315,000 shares of common stock.

Arcus Biosciences President Juan C. Jaen received grants of restricted stock units and stock options, signaling long-term incentive alignment.

Arcus Biosciences, Inc. reported an equity grant to General Counsel Carolyn C. Tang, including restricted stock units and stock options.

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, received grants of restricted stock units and stock options.

Arcus Biosciences, Inc. granted 21,050 restricted stock units and 14,050 stock options to Chief Accounting Officer Alexander Azoy.

Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, Inc., was granted 31,000 restricted stock units and 126,000 stock options.

Arcus Biosciences CEO Terry J. Rosen reported a charitable gift of 35,000 shares of common stock, executed under a Rule 10b5-1 plan.

Arcus Biosciences President Juan C. Jaen sold 31,823 shares of common stock on January 5, 2026, through a pre-arranged 10b5-1 trading plan.

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, sold 6,552 shares of common stock at $23.38 per share under a pre-arranged 10b5-1 trading plan.

Arcus Biosciences CEO Terry J. Rosen transferred 2,400 shares of common stock to family trusts, retaining voting and dispositive power.

Arcus Biosciences General Counsel Carolyn C. Tang sold shares totaling 14,468 to cover tax withholding obligations related to RSU vesting.

Arcus Biosciences' Chief Medical Officer, Richard Markus, sold shares to cover tax withholding obligations related to RSU vesting, not as a discretionary trade.

Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, reported sales of 8,832 common shares over three days in December 2025, primarily to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, sold shares to cover tax withholding obligations related to RSU vesting.

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold shares to cover tax withholding obligations related to RSU vesting, not as a discretionary trade.

Arcus Biosciences President Juan C. Jaen sold over 21,000 shares of common stock to cover tax withholding obligations related to RSU vesting.